These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 19616638)

  • 1. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
    Guo L; Dong Z; Guthrie H
    J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.
    Valentin JP; Hoffmann P; De Clerck F; Hammond TG; Hondeghem L
    J Pharmacol Toxicol Methods; 2004; 49(3):171-81. PubMed ID: 15172013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs.
    Kågström J; Sjögren EL; Ericson AC
    J Pharmacol Toxicol Methods; 2007; 56(2):186-93. PubMed ID: 17582787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
    Tabo M; Kimura K; Ito S
    J Pharmacol Toxicol Methods; 2007; 55(3):254-61. PubMed ID: 17229580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
    Guo L; Guthrie H
    J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
    Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
    J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model.
    Steidl-Nichols JV; Hanton G; Leaney J; Liu RC; Leishman D; McHarg A; Wallis R
    J Pharmacol Toxicol Methods; 2008; 57(1):9-22. PubMed ID: 17707659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between prolongation of QTc and prolongation of the peak of T (Tp) to the end of T (Te).
    Roche BM; Kijtawornrat A; Hamlin RL; Hamlin DM
    J Pharmacol Toxicol Methods; 2005; 52(1):178-81. PubMed ID: 15932797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ; Johnson DM; Weltens E; Lissens J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts.
    Cheng HC; Incardona J
    J Pharmacol Toxicol Methods; 2009; 60(2):174-84. PubMed ID: 19524054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the sedative agent, JM-1232(-) cause QT prolongation with subsequent torsades de pointes?
    Kato R; Watanabe R; Miki H; Ijiri Y; Hayashi T; Tanaka K
    Life Sci; 2009 Nov; 85(21-22):737-41. PubMed ID: 19833140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QTc shortening with a new investigational cancer drug: a brief case study.
    Himmel HM; Hoffmann M
    J Pharmacol Toxicol Methods; 2010; 62(1):72-81. PubMed ID: 20570746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability.
    Wisialowski T; Crimin K; Engtrakul J; O'Donnell J; Fermini B; Fossa AA
    J Pharmacol Exp Ther; 2006 Jul; 318(1):352-9. PubMed ID: 16614168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model.
    Morissette P; Nishida M; Trepakova E; Imredy J; Lagrutta A; Chaves A; Hoagland K; Hoe CM; Zrada MM; Travis JJ; Zingaro GJ; Gerenser P; Friedrichs G; Salata JJ
    J Pharmacol Toxicol Methods; 2013; 68(1):137-49. PubMed ID: 23649000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.
    Hondeghem LM; Carlsson L; Duker G
    Circulation; 2001 Apr; 103(15):2004-13. PubMed ID: 11306531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.
    Lu HR; Vlaminckx E; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2005; 52(1):90-105. PubMed ID: 15978848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.